Drug intelligence / Profile preview

ceritinib + ribociclib

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

Combination therapy consisting of ceritinib, an ALK inhibitor, and ribociclib, a CDK4/6 inhibitor. This combination targets both ALK-mediated signaling and cell cycle regulation through CDK4/6 inhibition. Preclinical data showed that combining these mechanisms may act synergistically to overcome drug resistance in ALK-positive cancers. In clinical studies, the combination demonstrated clinical activity with a manageable safety profile in patients with ALK-rearranged non-small cell lung cancer (NSCLC).

Brand names: KisqaliZykadia
Other names: ribociclib and ceritinibLEE011 + LDK378

Targets

ENTPD1 (Ectonucleoside triphosphate diphosphohydrolase 1)CDK6 (Cyclin-dependent kinase 6)ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)CDK4 (Cyclin-dependent kinase 4)

Beyond the preview

Go deeper on ceritinib + ribociclib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ceritinib + ribociclib.

Explore the full profile